Performance of cardiac PET/CT with and without phase analysis for detection of scar in cardiac sarcoidosis: Comparison to cardiac magnetic resonance imaging

Elwazir, Mohamed Y.; Bird, Jared G.; AbouEzzeddine, Omar F.; Chareonthaitawee, Panithaya; Blauwet, Lori A.; Collins, Jeremy D.; Gibbons, Raymond J.; Rodriguez-Porcel, Martin; Kamal, Hanan; Abdellah, Ahmed; Bois, John P.

doi:10.1007/s12350-020-02473-x

Cited by 6 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gated perfusion images permit assessment of left ventricular (LV) global and regional contractile function, providing important diagnostic and prognostic information. The addition of phase analysis to gated-PET resulted in improved detection of scar related to CS, superior to perfusion assessment alone [21]. The potential added value of quanti cation of myocardial blood ow and coronary ow reserve by PET in the diagnosis of CS has been explored in one study and remains to be further investigated [22].…”

Section: Pet and Cmr For Diagnosing Cardiac Sarcoidosismentioning

confidence: 99%

“…In contrast, the 2017 AHA/ACC/HRS guidelines recommend ICD implantation for primary precvention in patients with CS and LVEF < 35% (class I) and in patients with CS with any evidence of myocardial scar by CMR or cardiac PET/CT (class IIa indication) [72]. However, Elwazir et al recently demonstrated a low sensitivity for detection of myocardial scar by cardiac PET/CT compared to CMR [21], and in clinical practice assessment of myocardial scar is most commonly completed with CMR. One study identi ed an optimal cut-off for myocardial LGE of > 5.7% for the prediction of sudden cardiac death or ventricular arrhythmias [73].…”

Section: Risk Strati Cationmentioning

confidence: 99%

See 1 more Smart Citation

Multimodality imaging for diagnosis, risk stratification, and treatment monitoring of cardiac sarcoidosis

Young,

Raoult,

Leccisotti

et al. 2023

Clin Transl Imaging

Self Cite

View full text Add to dashboard Cite

Cardiac sarcoidosis (CS), with either extracardiac involvement or in isolation, is increasingly recognized.Complications from cardiac involvement are the leading cause of death in patients with sarcoidosis, rendering early detection extremely important given the signi cant therapeutic and prognostic implications. However, the diagnosis of CS remains challenging due to the lack of a reliable gold standard, largely due to the low sensitivity of traditional endomyocardial biopsy and patchy myocardial involvement. Recent advances in cardiac imaging with [18F] uoro-deoxyglucose positron emission tomography-computed tomography ([18F]FDG PET/CT) and cardiac magnetic resonance (CMR) have provided unprecedented information on the prevalence of CS and have revolutionized the diagnosis and management of CS patients. Abnormal PET/CMR ndings are now major criteria in societal guidelines to establish a probabilistic diagnosis of CS.This review provides a brief introduction to CS and a summary of current diagnostic criteria, followed by a review on the current use and strengths of PET/CT and CMR for diagnosis, risk strati cation and treatment response evaluation. CMR is the most robust technique to assess left ventricular function, to detect myocardial brosis and differentiate CS from other cardiomyopathies and has an excellent negative predictive value. On the other hand, [18F]FDG PET/CT is the modality of choice to assess active myocardial in ammation which may be amenable to immunosuppressive treatment as well as to detect extracardiac involvement, to identify potential biopsy sites and to monitor treatment e cacy.Understanding the complementary value of both techniques is crucial to the optimal utilization of advanced imaging in patients with CS. Lastly, some gaps are identi ed for future research. and effective treatment monitoring. [18F]FDG PET is the preferred modality for detecting active sarcoid lesions, identifying biopsy sites, and monitoring treatment response, while CMR demonstrates excellent negative predictive value and serves as the modality of choice for distinguishing CS from other cardiomyopathies. While the selection of advanced cardiac imaging modalities may vary based on local availability and expertise, adopting a multimodal imaging approach is paramount for the comprehensive diagnosis and management of cardiac sarcoidosis.

show abstract

Section: Pet and Cmr For Diagnosing Cardiac Sarcoidosismentioning

confidence: 99%